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Summary
Background: Family screening has been advocated as a means to reduce the major 
underdiagnosis of coeliac disease. However, the precise risk of the disease in rela-
tives and the impact of patient- and relative- related individual factors remain 
obscure.
Aims: To investigate the individual risk of coeliac disease among patients' relatives.
Methods: Altogether 2943 relatives of 624 index patients were assessed for the pres-
ence of previous coeliac disease diagnosis, or were screened for the disease. Coeliac 
disease- associated human leucocyte antigen (HLA) genotype was determined from 
all participants. The association between individual factors and new screening posi-
tivity was assessed by logistic regression.
Results: There were 229 previously diagnosed non- index relatives with coeliac 
disease and 2714 non- affected (2067 first- degree, 647 more distant) relatives. 
Of these 2714 relatives, 129 (4.8%) were screening- positive (first- degree 5.1%, 
second- degree 3.6%, more distant 3.5%). The combined prevalence of the previ-
ously diagnosed and now detected cases in relatives was 12.2% (6.3% clinically 
detected, 5.9% screen- detected). In univariate analysis, age <18 years at diagnosis 
(odds ratio 1.60, 95% CI 1.04- 2.45) in index, and age 41- 60 years (1.73, 1.10- 2.73), 
being a sibling (1.65, 1.06- 2.59) and having the high- risk genotype (3.22, 2.01- 5.15 
DQ2.5/2.5 or DQ2.5/2.2 vs other risk alleles) in relatives were associated with 
screening positivity. Only high- risk HLA remained significant (2.94, 1.80- 4.78) in 
multivariable analysis.
Conclusions: Unrecognised coeliac disease was common among at- risk relatives even 
in a country with an active case- finding policy, and also in relatives more distant than 
first- degree. The presence of a high- risk genotype was the most important predictor 
for screening positivity. ClinicalTrials.gov identifier NCT03136731.
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1  | INTRODUC TION
Coeliac disease is a gluten- driven chronic gastrointestinal condition 
affecting individuals with a predisposing human leucocyte antigen 
HLA- DQ2 and/or HLA- DQ8 haplogenotype.1 Estimated prevalence 
of the disease is up to 1%- 3% in general population, but currently, 
most of the affected patients remain unrecognised.2- 5 This substan-
tial underdiagnosis could be improved by active testing of either 
specific at- risk groups or even the whole population with serum coe-
liac autoantibodies. At present, most authorities do not recommend 
untargeted screening mainly because of inconsistent data on the 
prognosis of unrecognised coeliac disease at the population level.6- 9 
However, particularly, the first- degree (FDR) and, sometimes, also 
second- degree (SDR) relatives of patients are often considered to 
have a sufficiently high disease risk to justify screening.9- 13
Selecting an optimal screening strategy is complicated by a wide 
variation in the reported family risk14- 16 possibly due to different 
poorly defined patient- and relative- related individual factors, such 
as age at screening, gender, HLA haplogenotype and degree of con-
sanquinity.1,16- 23 Limited data on these factors make optimal timing 
of screening, testing of other than FDRs, and the benefits of genetic 
risk stratification debatable.13,15,16,23 The heterogenous and often 
small study cohorts and different diagnostic outcomes in earlier 
studies further hamper the interpretation of the results and empha-
sise the need for additional evidence.14 Besides optimised imple-
mentation of the screenings, better understanding of the individual 
risk factors could provide novel insights into pathogenesis. In fact, 
precise risk stratification in coeliac disease is becoming increasingly 
important as we may be entering the era of primary preventions.24,25
Here we aimed to study the impact of various index patient- and 
relative- related factors on the risk of coeliac disease. This was estab-
lished by serological and genetic testing of a large and well- defined 
cohort of relatives of previously diagnosed coeliac disease patients.
2  | METHODS
2.1 | Patients and study design
The study was conducted in Tampere University and Tampere 
University Hospital. The participants were enrolled by inviting 
children and adults with previously diagnosed coeliac disease and 
their close relatives to a voluntary family screening via newspaper 
announcements and local coeliac societies. The aim was to recruit 
particularly FDRs and SDRs of the index patients, although more 
distant relatives could also participate. All subjects reporting coe-
liac disease, or in the case of children, their parents/caregivers were 
interviewed systemically by a study nurse or a physician (File S1). 
Patient records were obtained with participants' permission in order 
to confirm the original diagnosis and other relevant medical data. 
Patients with lacking medical records or unclear diagnoses were ex-
cluded. Blood samples were collected from all study participants for 
the determination of coeliac disease serology and HLA type.
The first family member diagnosed was defined as the index if 
there was more than one coeliac disease patient in the same fam-
ily. The degree of consanguinity between index patients and rela-
tives was documented based on self- report by the participant or 
caregivers. The non- index family members were further divided 
into FDRs (siblings, parents and offspring), SDRs (grandparents, 
grandchildren, aunts, uncles, nieces, nephews and half- siblings) and 
more distant (first- and second- degree cousins, great- grandchildren, 
great- grandparents, great- uncles and great- aunts).26 The screened 
relatives were considered to belong to a multiple- case family if they 
had ≥1 FDR or SDR in addition to the index previously diagnosed 
with coeliac disease. Families with neither confirmed index patient 
nor any non- coeliac relatives to screen were excluded, as were indi-
viduals found to be unrelated to or having an unclear relation to the 
index patient.
2.2 | Ethics
The study design and recruitment of the participants were ap-
proved by the Ethics Committee of Pirkanmaa Hospital District. 
The Declaration of Helsinki was followed. The participants were in-
formed in advance of the purpose of the study and the significance 
of the screening results. All participants/caregivers provided written 
informed consent. The study is registered in ClinicalTrials.gov, iden-
tifier number NCT03136731.
2.3 | Clinical data
Demographic information was collected from all participants. In ad-
dition, age at diagnosis, severity of small- bowel mucosal damage27 
(partial- , subtotal- and total villous atrophy) as reported by the pa-
thologists and the presence of dermatitis herpetiformis or possible 
autoimmune co- morbidity (eg type 1 diabetes, Sjögren's syndrome, 
Addison's disease) were recorded from the previously diagnosed 
coeliac disease patients. Possible symptoms preceding the diagnosis 
or screening were assessed from the previously diagnosed coeliac 
disease patients and new screening- positive relatives.
2.4 | Serological testing, genetics and 
diagnostic outcome
Serum endomysial (EmA) and tissue transglutaminase antibodies 
(TGA) were tested from all relatives without previous coeliac disease 
diagnoses. EmAs were measured by indirect immunofluorescence 
using the human umbilical cord as an antigen and considering titres 
1: ≥5 positive.28 An enzyme- linked immunosorbent assay (QUANTA 
Lite h- tTG IgA; INOVA Diagnostics) was used to test TGA, applying 
a cut- off >20 U/L for seropositivity.29 IgG- class EmA and TGA were 
used only if IgA deficiency was suspected based on abnormal EmA 
staining pattern and low TGA.30
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Genotyping for the coeliac disease- associated HLA alleles was 
performed using the SSPTM DQB1 low- resolution kit (Olerup SSP 
AB), DELFIA® Coeliac Disease Hybridization Assay Kit (PerkinElmer 
Life and Analytical Sciences, Wallac Oy) or tagging SNP approach.31 
The genotypes were categorised based on predisposing alleles 
for coeliac disease to high risk (A1*05- B1*0201/A1*05- B1*0201 
[DQ2.5/2.5] or A1*05- B1*0201/A1*02- B1*0202 [DQ2.5/2.2]), in-
termediate risk (A1*05- B1*0201/X [DQ2.5/X], A1*05- B1*0201/
A1*03- B1*0302 [DQ2.5/8], A1*02- B1*0202 [DQ2.2/2.2 and 
DQ2.2/X], A1*02- B1*0202/A1*03- B1*0302 [DQ2.2/8] and 
A1*03- B1*0302 [DQ8/8 and DQ8/X]) and low risk (DQ2/DQ8 
negative).32
The main diagnostic outcome— considered to signify coeliac dis-
ease in the present study— was positivity for both TGA and EmA and 
the presence of the disease- associated HLA DQ2 and/or DQ8 hap-
lotype.23 The possible new seropositive family members were either 
recruited for prospective studies or received a referral to health care 
for possible additional investigations or follow- up outside the study 
protocol.
2.5 | Statistics
The results are given either as number of cases, percentages, me-
dians with lower and upper quartiles or as odds ratios (OR) with 
95% CIs. The FDRs were analysed both as a whole group and also 
separately (offspring, siblings, parents) and SDRs and more distant 
relatives as whole groups. Statistical significance of categorical vari-
ables was assessed by chi- square test and that of continuous vari-
ables by Mann- Whitney test, considering P values <0.05 significant. 
The association between index- related factors and positive screen-
ing outcomes was studied by setting the properties of the index as 
variables for each screened relative. The ORs for new seropositivity 
were then evaluated by binary logistic regression first in univariate 
analysis. The reference category was defined as the group with the 
greatest number of subjects. Next, statistically significant independ-
ent risk predictors were determined by multivariable binary logistic 
regression for characteristics significant in the univariate analysis. 
Three different models were applied for the multivariable analysis 
as follows: Model 1 notifies the significant characteristics of the 
screened relative excluding HLA, Model 2 the significant charac-
teristics of both relative and index excluding HLA and Model 3 the 
characteristics of Model 2 and high- vs intermediate- risk HLA of the 
screened relative. Statistical analyses were performed using either 
SPSS Statistics for Windows (IBM Corp.) or Confidence Interval 
Analysis Program33 as appropriate.
3  | RESULTS
Altogether 4155 subjects were enrolled (Figure 1). White North 
European origin was the only ethnic background reported. After ap-
plying the exclusion criteria, 624 index patients with coeliac disease 
and 2943 of their relatives were included. Among the relatives, there 
were altogether 229 previously diagnosed non- index coeliac disease 
patients in 152 multiple- case families (Figure 1), including 45 who 
were screen- detected. The characteristics of the index and non- 
index coeliac disease patients are shown in Table S1. The median 
age of the 2714 relatives without previous coeliac disease diagnosis 
was 36 (range 1- 91) years and 55.5% were females. Altogether 2067 
(76.2%) were FDRs (30.1% offspring, 28.9% siblings, 17.2% parents), 
534 (19.7%) SDRs and 113 (4.2%) more distant relatives. The distri-
bution of HLA risk alleles did not differ significantly either between 
men and women or between FDRs, SDRs and more distant relatives 
(data not shown).
Altogether 129 (4.8%) of the 2714 screened relatives with-
out previously diagnosed coeliac disease were screening- positive 
(Figure 1), the prevalence being 5.1% in FDRs (siblings 6.5%, par-
ents 4.7%, offspring 4.0%), 3.6% in SDRs and 3.5% in other rel-
atives. The combined prevalence of the newly detected relatives 
and previous coeliac disease in non- index relatives was 12.2% 
(6.3% clinically detected, 5.9% screen- detected) as a whole and 
12.5% in FDRs, 10.9% in SDRs and 12.8% in more distant relatives 
(Figure 1). Of the 2714 screened relatives, three had IgA deficiency 
and one EmA positive subject had negative (19 U/L) TGA. High- risk 
HLA haplogenotypes were more frequent in the newly detected 
screening- positive relatives than in screening- negative relatives, 
whereas the groups were comparable in demographic data, preva-
lence of multiple- case families and relation with the index (Table 1). 
The presence of screening positivity was not affected by sex 
(FDR: sisters 6.2% vs brothers 6.9%, P = 0.670; mothers 5.1% vs 
fathers 4.1%, P = 0.591; daughters 4.1% vs sons 4.3%, P = 0.766; 
SDR: women 4.1% vs men 2.9%, P = 0.430; more distant relatives: 
women 3.0% vs men 4.3%, P = 1.000). Clinical data were available 
from 87 of the new screening- positive relatives, of whom 62.1% 
reported experiencing possible coeliac disease- related symptoms 
before the study.
When the newly detected screening- positive FDRs (n = 106) and 
SDRs (n = 19) were compared, the former were older (median 42 
vs 29 years, P = 0.007) and less often below 18 years of age (17.9% 
vs 44.4%, P = 0.026) and members of multiple- case families (20.8% 
vs 47.4%, P = 0.020), whereas there were no significant differences 
between the FDRs and SDRs in sex or distribution of HLA risk alleles 
(data not shown).
The highest frequencies of both previously diagnosed coeliac 
disease and screening positivity detected in the present study 
were seen in subjects aged between 41 and 50 years of age and 
the lowest frequencies in those older than 60 years (Figure 2). The 
overall prevalence among relatives was highest in siblings, and 
there was a trend for decreasing frequency of new screening pos-
itivity from siblings to more distant relatives, while the prevalence 
was distributed more equally among the previously diagnosed pa-
tients (Figure 3).
Age below 18 years at diagnosis in index patients and age be-
tween 41 and 60 years at screening, being a sibling, and carrying 
high- risk HLA alleles in relatives were significantly associated with 
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screening positivity in univariate regression analysis (Table 2). 
In multivariable analysis, a significant association was observed 
with being a sibling in Model 1 (notifying consanguinity and age at 
screening) and with the presence of high- risk HLA group in Model 
3 (notifying all characteristics significant in univariate analysis) 
(Table 2).
4  | DISCUSSION
We found unrecognised coeliac disease to be common (4.8%) among 
the index patients' relatives despite a high rate of previously diag-
nosed family members. The combined prevalence of all relatives de-
tected either by clinical suspicion (6.3%) or by present and earlier 
screening (5.9%) was 12.2%, which is approximately five times our 
population- based estimate.4 Most earlier studies have concentrated 
on FDRs, in whom prevalences have ranged from 1.3% to 44.1%.14,34 
This heterogeneity may be due to differences in the overall incidence 
of coeliac disease1 and demographic features of the relatives. In fact, 
most earlier studies have been small and included only a few hun-
dred screened FDRs.14 Another salient factor may be the definition 
of screening positivity adopted. The seropositivity definition used 
here, providing that validated tests are used, may yield less biased 
results than duodenal biopsy, which is frequently declined, particu-
larly by asymptomatic screening- positive subjects.35,36 Serology 
is actually gaining a more important role in screening studies and 
even diagnosis, in spite of not yet being a universally accepted diag-
nostic criterion.37- 39 In the few relatively large studies with at least 
partially similar design, 4.2%- 5.6% of FDRs have been screening- 
positive.36,40,41 Closer to our findings, Rubio- Tapia et al22 reported 
a prevalence of 16.4% in FDRs in which they— exceptionally— also 
counted the proportion (5.1%) of previous diagnoses in non- index 
family members.
In detailed analysis, siblings had the highest frequency of sero-
positivity among the FDRs. Despite concurring with previous re-
ports,14 the differences between consanguinities were smaller here 
and not significant in multivariable analysis, possibly because con-
founding factors have not been similarly considered in earlier stud-
ies.16,20 Likewise, although the SDRs and more distant relatives had 
less often newly detected seropositivity than the FDRs, the groups 
did not differ in either the combined prevalences or multivariable 
analysis. This might be due to similar HLA distribution within the 
groups and indicates that coeliac disease risk in other relatives than 
FDRs is higher than previously thought.15,39,40 It must be noted, 
however, that seropositive SDRs belonged more often to multiple- 
case families than the FDRs, although this was not a significant risk 
F I G U R E  1   Flowchart of the study. CD, coeliac disease
4155 volunttered CD patients and relatives in 
732 families
3755 CD patients and relatives in 630 families
134 patients without confirmed CD
- 51 medical records missing 
- 83 unclear diagnosis
31 CD patients without non-CD relatives 
235 non-CD relatives without CD index
178 with unclear or no relationship with 
the CD index
129 with new screen-
detected CD
3567 CD patients and relatives in 624 families,
including 624 confirmed CD index patients
2714 underwent 
screening
2585 with negative 
screening
184 with previous 
clinically detected CD
45 with previous 
screen-detected CD
2943 relatives of the 624 CD index patient
229 with previously 
diagnosed CD
(non-index)
Prevalence of CD in relatives 12.2% 
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factor as such. However, the somewhat arbitrary classification of 
index in the multiple- case families according to the order of the 
coeliac disease diagnosis and the general homogeneity of Finnish 
population may have affected the analysis.40 Of note, although evi-
dence has been scant,15 the American College of Gastroenterology 
recommends screening more distant relatives than FDRs,13 and our 
findings give further support for this approach. However, additional 
studies on this issue are warranted.
Age at screening was not a significant factor associated with 
screening positivity in multivariable analysis, but the prevalence of 
affected cases increased from childhood to middle age, after which 





P valuen % n %
Age at screening, median (Q1, Q3), y 40 (20, 53) 36 (17, 55) 0.556
Age <18 y at screening 29 22.7 667 26.0 0.404
Women 72 55.8 1435 55.5 0.946
Member of multiple- case familyb  35 27.1 631 24.4 0.483
Degree of consanguinity with index
First- degree relatives 106 82.2 1961 75.9 0.260c 
Sibling 51 48.1 732 37.3 0.073d 
Offspring 33 31.1 783 39.9
Parent 22 20.8 446 22.7
Second- degree relativese  19 14.7 515 19.9
More distant relatives 4 3.1 109 4.2
HLA risk groupf  <0.001
Highg  27 26.5 156 7.0
Intermediateh  75 73.5 1394 62.3
Lowi  0 0 686 30.7
aPositive endomysium and transglutaminase antibodies and presence of human leucocyte antigen 
(HLA) DQ2 and/or DQ8.
bAt least two first- or second- degree relatives previously diagnosed with coeliac disease.
cFirst- degree vs second- degree vs more distant.
dAmong first- degree relatives.
eGrandparent, grandchild, aunt, uncle, niece, nephew, half- sibling.
fData missing from 376 screened relatives.
gDQ2.5 homozygotes and DQ2.5/2.2.
hDQ2.5 heterozygotes or DQ2.2 and/or DQ8 positive.
iDQ2 and DQ8 negative.
TA B L E  1   Clinical characteristics and 
HLA distribution in 2714 at- risk relatives 
with positivea or negative screening 
outcome
F I G U R E  2   Age distribution at coeliac 
disease diagnosis in previously diagnosed 
index patients and non- index relatives 
with coeliac disease and current age of 



















Previously screen-detected non-index patients 
Previously clinically-detected non-index patients 
Coeliac disease index patients
Screen-detected relatives in the present study 
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F I G U R E  3   Percentage of coeliac 
disease in the relatives of index 
patients, divided according to degree of 


























Relation with the coeliac disease index patient
Screen-detected relatives in the present study 
Previous screen-detected coeliac disease
Previous clinically-detected coeliac disease




Model 1b Model 2c Model 3d
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Index characteristics
Age <18 y at diagnosis 1.60 (1.04- 2.45) 1.34 (0.80- 2.23) 1.41 (0.80- 2.51)
Women 0.73 (0.49- 1.07)
High vs intermediate risk HLA 1.37 (0.89- 2.12)
Dermatitis herpetiformis 0.91 (0.55- 1.52)
Autoimmune co- morbidity 1.39 (0.86- 2.23)
TVA vs PVA/SVA 1.02 (0.68- 1.62)
Relative characteristics
Age <18 y at screening 0.84 (0.55- 1.28)
Women 1.01 (0.71- 1.45)
Highe  vs intermediatef  risk HLA 3.22 (2.01- 5.15) 2.94 (1.80- 4.78)
Consanguinity with index
Offspring 1 1 1 1
Sibling 1.65 (1.06- 2.59) 1.67 (1.00- 2.79) 1.51 (0.88- 2.58) 1.30 (0.71- 2.35)
Parent 1.17 (0.67- 2.03) 1.58 (0.82- 3.05) 1.29 (0.61- 2.72) 1.05 (0.45- 2.44)
Second- degree relative 0.88 (0.49- 1.57) 0.86 (0.48- 1.55) 0.84 (0.46- 1.52) 0.90 (0.46- 1.76)
More distant relative 0.87 (0.30- 2.51) 0.91 (0.31- 2.62) 0.84 (0.29- 1.27) 1.24 (0.41- 3.76)
Multiple- case family 1.15 (0.77- 1.72)
Age at screening, years
0- 20 1 1 1 1
21- 40 1.06 (0.65- 1.74) 0.97 (0.58- 1.61) 1.01 (0.60- 1.69) 1.06 (0.59- 1.91)
41- 60 1.73 (1.10- 2.73) 1.21 (0.71- 2.07) 1.30 (0.75- 2.26) 1.62 (0.88- 2.97)
61- 0.70 (0.37- 1.33) 0.48 (0.23- 1.01) 0.57 (0.26- 1.27) 0.51 (0.19- 1.34)
Note: Characteristics notified in multivariable analysis were bconsanguinity with the index and relative's age at screening; cmodel 1 and age of index 
<18 y at diagnosis; dmodel 2 and high vs intermediate risk HLA of relatives.
Abbreviations: OR, odds ratio; PVA, partial villous atrophy; SVA, subtotal villous atrophy; TVA, total villous atrophy.
aPositive endomysium and transglutaminase antibodies and presence of human leucocyte antigen (HLA) DQ2 and/or DQ8.
eDQ2.5 homozygotes and DQ2.5/2.2.
fDQ2.5 heterozygotes and DQ2.2 and/or DQ8 positive.
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overall prevalence of coeliac disease by age,4,17,42 whereas the later 
decrease could be caused by a higher frequency of seronegative dis-
ease among the elderly.43 Another explanation could be increased 
mortality in unrecognised diseases, but this is debatable.44- 47 
Although interpretation is complicated by temporal changes in the 
recognition and true prevalence of coeliac disease,4,48 our results 
suggest that age should not affect the implementation of family 
screening. A more challenging issue is the follow- up of the seroneg-
ative relatives.16,41 Further evidence is needed, but a previously re-
ported peak in the seroconversion rate in early life and possible risk 
of permanent complications in growing children could justify more 
frequent re- testing in childhood.18,49,50 Of note, somewhat contrary 
to some earlier reports,4,14 sex had no significant effect here. This 
finding should be interpreted with some caution due to the high 
proportion of women among the index and non- index patients and 
possible gender differences in healthcare- seeking behavior.51 On 
the other hand, there are also previous reports consistent with our 
findings36 and it is possible that stronger HLA risk in family mem-
bers independent of sex factors might contribute. Unfortunately, we 
were not able to study the role of symptoms but based on previous 
evidence they are a poor predictor of coeliac disease in subjects un-
dergoing screening.52- 54
The presence of a high- risk haplotype was the only factor sig-
nificantly affecting (OR ~3) the risk of newly identified screening 
positivity in multivariable analysis and clearly overrode the other 
hypothesised factors. Similar findings have been reported in a few 
smaller studies.16,20 In light of these findings, and that the high- risk 
haplotype may even increase the risk for complications,55 determi-
nation of the HLA genotype could be beneficial, as it would make it 
possible to target screening most actively at those with high genetic 
risk and even to omit testing of low- risk relatives. It must, however, 
be realised that most of the affected relatives still carry the much 
more frequent intermediate- risk haplotypes and the majority of 
cases would thus be missed if only high- risk subjects were included. 
Although more studies are needed, the role of HLA risk group de-
termination may be more useful in re- screening of initially seroneg-
ative relatives, since making a distinction between the high- and 
intermediate- risk HLA might help to target the possible re- testing, 
as also suggested by Wessels et al.16 In the future, improved genetic 
score considering the additional contribution of non- HLA coeliac 
disease risk variants to disease risk of, as well as more precise strati-
fication of the HLA- DQ alleles, might enable more precise screening 
protocols.56- 58 In any case, before a more specific genetic risk score 
is validated, serological testing of at least all FDRs after an index 
patient is diagnosed likely remains the simplest and most effective 
approach for the initial screening.
4.1 | Strengths and limitations
The main strengths of our study were the exceptionally large and 
well- defined cohort of index patients and their relatives, the me-
ticulously collected family trees and the knowledge of various 
individual factors. Furthermore, the screening was conducted 
with well- validated serological tests, although only IgA class as-
says were systematically used. As a limitation, we had no exact 
data on those refusing to participate in the study or the individual 
symptoms or gluten consumption of the relatives. Furthermore, al-
though largely as a whole, the study may still have been too small to 
reveal all significant associations in the regression analysis, and the 
high proportion of previous diagnoses— a sign of active case finding 
and at- risk group screening— further complicates interpretation of 
the results. It must also be noted that our participants were ethni-
cally very homogeneous which, although beneficial in association 
analyses, for example, may overestimate the coeliac disease risk 
of more distant relatives than FDRs and limit the generalisability 
of the study.
4.2 | Conclusions
The prevalence of unrecognised coeliac disease was high in all ages 
and also in more distant than FDRs despite a high rate of previously 
diagnosed non- index relatives. Moreover, further supporting more 
active screening, the diagnostic yield was suboptimal even in a coun-
try with high coeliac disease awareness and broad healthcare cover-
age. The presence of the high- risk genotype is the most important 
predictor for coeliac disease and HLA determination could thus be 
useful to target serological screening of at- risk relatives.
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